MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases

Journal of Immunotherapy

Volumn 39, Issue 4, 2016, Pages 181-187

  Kerkar, Sid P ^a   Wang, Zeng Feng ^b   Lasota, Jerzy ^b   Park, Tristen ^b   Patel, Krishna ^b   Groh, Eric ^b   Rosenberg, Steven A ^b   Miettinen, Markku M ^b  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cancer testis antigens; Immuneescape; Immunohistochemistry; Immunotherapy; MAGE A; NYESO; Predictive markers; Prognostic markers; Tissue arrays

Indexed keywords

CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN A; NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA 1 ANTIGEN; UNCLASSIFIED DRUG; CTAG1B PROTEIN, HUMAN; MAGEA1 PROTEIN, HUMAN; MELANOMA ANTIGEN; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANUS CARCINOMA; ARTICLE; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BREAST CARCINOMA; CELL NUCLEUS; COLORECTAL CARCINOMA; CYTOPLASM; ENDOMETRIUM CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GERM CELL TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; NEOPLASM; NON SEMINOMATOUS GERMINOMA; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SEMINOMA; SKIN CARCINOMA; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; STOMACH ADENOCARCINOMA; THYMUS CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA; COHORT ANALYSIS; ESOPHAGUS TUMOR; HEAD AND NECK TUMOR; METABOLISM; METASTASIS; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84964866581     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000119     Document Type: Article

References (27)

1. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615-625.
2. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.
3. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002;188:51-64.
4. Aung PP, Liu YC, Ballester LY, et al. Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol. 2014;45:259-267.
5. Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012;25:854-858.
6. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019-1027.
7. Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NYESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 2003;3:19.
8. Kurashige T, Noguchi Y, Saika T, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 2001;61:4671-4674.
9. Bolli M, Schultz-Thater E, Zajac P, et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer. 2005;115:960-966.
10. Akcakanat A, Kanda T, Koyama Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004;54:95-100.
11. Zhang WM, Xiao G, Xie D, et al. Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma. Ai Zheng. 2005;24:622-626.
12. Prasad ML, Jungbluth AA, Patel SG, et al. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck. 2004;26: 1053-1057.
13. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001;92:856-860.
14. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63:6076-6083.
15. Fossa A, Berner A, Fosså SD, et al. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate. 2004;59:440-447.
16. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 2003;3:10.
17. Kageyama S, Ikeda H, Miyahara Y, et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res. 2015;21:2268-2277.
18. Bergeron A, Picard V, LaRue H, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer. 2009;125:1365-1371.
19. Sang M, Lian Y, Zhou X, et al. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011;29: 8496-8500.
20. Miettinen M. A simple method for generating multitissue blocks without special equipment. Appl Immunohistochem Mol Morphol. 2012;20:410-412.
21. Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009;15:933-942.
22. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907-922.
23. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
24. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
25. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology. 2014;28(suppl 3): 39-48.
26. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348: 62-68.
27. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72: 3125-3130.